Pembrolizumab monotherapy in advanced triple-negative breast cancer

Affiliations

¹ Department of Medical Oncology, Dr B R Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi 110029, India.
² Department of Medical Oncology, Dr B R Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi 110029, India. Electronic address: ajaygogia@gmail.com.

Comment

Shuvadeep Ganguly et al. Lancet Oncol. 2021 Jun.

. 2021 Jun;22(6):e224.

doi: 10.1016/S1470-2045(21)00249-7.

¹ Department of Medical Oncology, Dr B R Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi 110029, India.
² Department of Medical Oncology, Dr B R Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi 110029, India. Electronic address: ajaygogia@gmail.com.

No abstract available

Conflict of interest statement

We declare no competing interests.

Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial.
Winer EP, Lipatov O, Im SA, Goncalves A, Muñoz-Couselo E, Lee KS, Schmid P, Tamura K, Testa L, Witzel I, Ohtani S, Turner N, Zambelli S, Harbeck N, Andre F, Dent R, Zhou X, Karantza V, Mejia J, Cortes J; KEYNOTE-119 investigators. Winer EP, et al. Lancet Oncol. 2021 Apr;22(4):499-511. doi: 10.1016/S1470-2045(20)30754-3. Epub 2021 Mar 4. Lancet Oncol. 2021. PMID: 33676601 Clinical Trial.